[
  {
    "report_key": "2026:q4",
    "period_label": "2026 Q4",
    "date": "2026-07-02",
    "title": "Kvartalsrapport Q4 2026",
    "original_title": "Cinclus Pharma has Reached Enrollment Target in Phase III HEEALING1 Study - Topline Results Expected Q4 2026",
    "category": "Investor News",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b5e84c2227e5fc14ba9779f51ef381d53&lang=en&src=listed",
    "language": "en",
    "report_type": "interim-report",
    "fiscal_year": 2026,
    "quarter": "q4",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2026",
        "title": "Kvartalsrapport Q4 2026",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a282bcf2cda2ef27a9ceecc51f4a75b2a",
        "date": "2026-07-02",
        "period": "2026-q4",
        "form_type": "interim-report",
        "report_key": "2026:q4",
        "filename": "Cinclus_Pharma_has_Reached_Enrollment_Target_in_Phase_III_HEEALING1_Study_-_Topline_Results_Expe.pdf",
        "text_chars": 7132,
        "sha256": "a3ade84f3ebb56a475e5d9cba22fbf945d71ded11eb8759c7ce1f445395c7780",
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026",
        "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026",
        "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2026/part-001.html",
            "chars": 7132
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2026:q1",
    "period_label": "2026 Q1",
    "date": "2026-05-13",
    "title": "Kvartalsrapport Q1 2026",
    "original_title": "Delårsrapport januari-mars 2026 - Fas III-studien närmar sig full rekrytering",
    "category": "Interimsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=be3aea57a7868ab4df3cb80e874ac75dd&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2026,
    "quarter": "q1",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
        "title": "Kvartalsrapport Q1 2026",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/ac6dcc7bbc6692a0f752605df5f04d8c7",
        "date": "2026-05-13",
        "period": "2026-q1",
        "form_type": "interim-report",
        "report_key": "2026:q1",
        "filename": "Delarsrapport_Januari_Mars_2026.pdf",
        "text_chars": 62470,
        "sha256": "f3311b7e233e8d622d65baec7fcfd20c6cfb20db47f5867b579282da6260950f",
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
        "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
        "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
            "chars": 62470
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2025:annual",
    "period_label": "2025 Årsredovisning",
    "date": "2026-04-16",
    "title": "Årsredovisning 2025",
    "original_title": "Cinclus Pharmas offentliggör årsredovisning för 2025",
    "category": "Bokslut och Verksamhetsberättelse",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b93dd7b9b8d76ef21dd41b14463b1fc99&lang=sv&src=listed",
    "language": "sv",
    "report_type": "annual-report",
    "fiscal_year": 2025,
    "quarter": "annual",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-arsredovisning-2025",
        "title": "Årsredovisning 2025",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a76f761d15875030f49691cddf9148aa7",
        "date": "2026-04-16",
        "period": "2025-annual",
        "form_type": "annual-report",
        "report_key": "2025:annual",
        "filename": "Cinclus_Pharma_Arsredovisning_2025.pdf",
        "text_chars": 281267,
        "sha256": "7877b912af411f33be92b57647a1b704b119ac2f78845ef43255af100f8ac4bc",
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025",
        "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025",
        "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
            "chars": 172584
          },
          {
            "number": 2,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
            "chars": 108681
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2025:q4",
    "period_label": "2025 Q4",
    "date": "2026-02-18",
    "title": "Kvartalsrapport Q4 2025",
    "original_title": "Meddelande om korrigering av Cinclus Pharmas bokslutskommuniké för 2025",
    "category": "Bokslutskommuniké",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=bca8f507478de38bfd6c410b868f0d8f0&lang=sv&src=listed",
    "language": "sv",
    "report_type": "year-end-report",
    "fiscal_year": 2025,
    "quarter": "q4",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
        "title": "Kvartalsrapport Q4 2025",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/aaba771d2d1fe265b79612ee155efcae6",
        "date": "2026-02-18",
        "period": "2025-q4",
        "form_type": "year-end-report",
        "report_key": "2025:q4",
        "filename": "Bokslutskommunike_2025.pdf",
        "text_chars": 95665,
        "sha256": "77b5757b975035b7c1264aa7d4b19696a6a8728fa9582c33f10ab218ab48c216",
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
        "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
        "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
            "chars": 95665
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2025:q3",
    "period_label": "2025 Q3",
    "date": "2025-11-20",
    "title": "Kvartalsrapport Q3 2025",
    "original_title": "A positive start to the Phase III study",
    "category": "Interim report (Q1 and Q3)",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=ba561db31bee3b57137eaf7a01ba26e09&lang=en&src=listed",
    "language": "en",
    "report_type": "interim-report",
    "fiscal_year": 2025,
    "quarter": "q3",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
        "title": "Kvartalsrapport Q3 2025",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a05ae3e9c05f619a0eb7dfed28ab19159",
        "date": "2025-11-20",
        "period": "2025-q3",
        "form_type": "interim-report",
        "report_key": "2025:q3",
        "filename": "Interim_Report_Cinclus_Pharma_Jan_Sep_2025_1.pdf",
        "text_chars": 101924,
        "sha256": "5f0c61e5739da3cc0e59df0afcf8d5a3c7eb54a4ad52037bd6cb26409c5ae795",
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
        "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
        "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
            "chars": 101924
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2025:q2",
    "period_label": "2025 Q2",
    "date": "2025-08-20",
    "title": "Kvartalsrapport Q2 2025",
    "original_title": "Delårsrapport januari-juni 2025 - Stärkt position för framtida värdeskapande",
    "category": "Halvårsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b1b37dbdf834ed3bc00471f73070318ab&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2025,
    "quarter": "q2",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
        "title": "Kvartalsrapport Q2 2025",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/ad3f2a1c26ea557b4f7522bb4bb94902f",
        "date": "2025-08-20",
        "period": "2025-q2",
        "form_type": "interim-report",
        "report_key": "2025:q2",
        "filename": "Delarsrapport_Cinclus_Pharma_Jan_Juni_2025_1.pdf",
        "text_chars": 95184,
        "sha256": "3bd0c85b4b77fcbd10ad07eeb719bb2a751b0bffa1f8e92dc8cee8e6a398e5d9",
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
        "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
        "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
            "chars": 95184
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2025:q1",
    "period_label": "2025 Q1",
    "date": "2025-05-20",
    "title": "Kvartalsrapport Q1 2025",
    "original_title": "Delårsrapport januari-mars 2025",
    "category": "Interimsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=bb2cbc8dcf4b4663856512d86f2a153bb&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2025,
    "quarter": "q1",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
        "title": "Kvartalsrapport Q1 2025",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a522e89c5664a1db22371aaf9c69463d2",
        "date": "2025-05-20",
        "period": "2025-q1",
        "form_type": "interim-report",
        "report_key": "2025:q1",
        "filename": "Cinclus_Pharma_Delarsrapport_Kvartal_1_2025.pdf",
        "text_chars": 87832,
        "sha256": "8a85b0ab839af5e12c95b5c540a2c1f0ce44634266fe922ef66c78020ac0c5a6",
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
        "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
        "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
            "chars": 87832
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2024:annual",
    "period_label": "2024 Årsredovisning",
    "date": "2025-04-30",
    "title": "Årsredovisning 2024",
    "original_title": "Meddelande om korrigering av Cinclus Pharmas offentliggjorda årsredovisning för 2024",
    "category": "Bokslut och Verksamhetsberättelse",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=bb2a8dd66cef72cfcfa1373ac38481409&lang=sv&src=listed",
    "language": "sv",
    "report_type": "annual-report",
    "fiscal_year": 2024,
    "quarter": "annual",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-arsredovisning-2024",
        "title": "Årsredovisning 2024",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a394e7e17c7b2dcdbe58c1dbb2ba29122",
        "date": "2025-04-30",
        "period": "2024-annual",
        "form_type": "annual-report",
        "report_key": "2024:annual",
        "filename": "Cinclus_Pharma_Arsredovisning_2024_2.pdf",
        "text_chars": 342936,
        "sha256": "7cd593a96ce1e297e8c56d2afc904a9d469fc924881517ad61a704f46ba0258e",
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024",
        "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024",
        "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
            "chars": 178763
          },
          {
            "number": 2,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
            "chars": 164171
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2024:q4",
    "period_label": "2024 Q4",
    "date": "2025-02-20",
    "title": "Kvartalsrapport Q4 2024",
    "original_title": "Bokslutskommuniké januari - december 2024",
    "category": "Bokslutskommuniké",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b3d10e6c0b3d95c27fa9972ebca434110&lang=sv&src=listed",
    "language": "sv",
    "report_type": "year-end-report",
    "fiscal_year": 2024,
    "quarter": "q4",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
        "title": "Kvartalsrapport Q4 2024",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a7f80acd423cf29ac5a7847d13df1c03a",
        "date": "2025-02-20",
        "period": "2024-q4",
        "form_type": "year-end-report",
        "report_key": "2024:q4",
        "filename": "Bokslutskommunike_2024_Cinclus_Pharma.pdf",
        "text_chars": 92082,
        "sha256": "89d722bc452c3b5e5ee60f575da7fc0b2883a79ec60c48cf27ccb461d70f8ae8",
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
        "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
        "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
            "chars": 92082
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2024:q3",
    "period_label": "2024 Q3",
    "date": "2024-11-14",
    "title": "Kvartalsrapport Q3 2024",
    "original_title": "Delårsrapport januari - september 2024",
    "category": "Interimsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=ba99df0ca79c2283630cd0ad4c55042dc&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2024,
    "quarter": "q3",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
        "title": "Kvartalsrapport Q3 2024",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a44e5a06d73f6dbbffa3866facd8f337d",
        "date": "2024-11-14",
        "period": "2024-q3",
        "form_type": "interim-report",
        "report_key": "2024:q3",
        "filename": "Cinclus_Pharma_Delarsrapport_Januari_-_September_2024.pdf",
        "text_chars": 91562,
        "sha256": "b7243893f5c7fb4ff2bf11960b9e4b96ac38a00df1c81cb01f7c4780a4ac51aa",
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
        "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
        "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
            "chars": 91562
          }
        ]
      }
    ],
    "alternatives": []
  },
  {
    "report_key": "2024:q2",
    "period_label": "2024 Q2",
    "date": "2024-08-29",
    "title": "Kvartalsrapport Q2 2024",
    "original_title": "CINCLUS PHARMA DELÅRSRAPPORT APRIL-JUNI 2024",
    "category": "Halvårsrapport",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://view.news.eu.nasdaq.com/view?id=b9cfcb0ad50550326861f2f8eef10edcd&lang=sv&src=listed",
    "language": "sv",
    "report_type": "interim-report",
    "fiscal_year": 2024,
    "quarter": "q2",
    "documents": [
      {
        "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
        "title": "Kvartalsrapport Q2 2024",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://attachment.news.eu.nasdaq.com/a7c94962bd25075b3f3ab2a4e60e68e9d",
        "date": "2024-08-29",
        "period": "2024-q2",
        "form_type": "interim-report",
        "report_key": "2024:q2",
        "filename": "Cinclus_Pharma_Delarsrapport_Januari_-_Juni_2024.pdf",
        "text_chars": 87625,
        "sha256": "5c0f583e66122910127e5377ca850253b3f7b7a228c0138a5c8540b88987d2d1",
        "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
        "absolute_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
        "txt_url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
        "absolute_txt_url": "https://spela.port0.org/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
        "parts": [
          {
            "number": 1,
            "url": "/company/cinclus-pharma-holding-ab/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
            "chars": 87625
          }
        ]
      }
    ],
    "alternatives": []
  }
]